Emory University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Emory University sits in the top decile of US sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count).

1,208 total trials 208 currently recruiting 767 completed early-phase tilt top decile by trial count

Emory University: 1,208 sponsored US clinical trials, 208 recruiting.

Emory University sponsors 1,208 registered US clinical trials on ClinicalTrials.gov, 208 of them currently recruiting, and 767 completed. 170 of these trials are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 12 trials.

Top-decile sponsor footprint

Emory University ranks in the top decile of sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 47/100

767 of 926 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,208 total, page 3 of 25

RECRUITING

F18-MHF: Orthopedic Implants-Associated Infection Detection

NCT05889286

RECRUITING Early Phase 1

Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases

NCT06328686

RECRUITING Phase 2

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

NCT05741164

RECRUITING NA

Pectoralis Minor Release Versus Non-release in RSA

NCT06292169

RECRUITING Phase 2

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

NCT06423326

RECRUITING

Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy

NCT06595160

RECRUITING Phase 2

Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers

NCT06492070

RECRUITING NA

Sleep Enhancement for Older Adults Living With Memory Loss And Their Care Partners

NCT06250725

RECRUITING Phase 2

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

NCT06495125

RECRUITING NA

Inspiring Seniors Towards Exercise Promotion to Protect Cognition

NCT06496425

RECRUITING NA

Behavioral Intervention to Reduce Stress Among Black Gender Minority Women

NCT05436106

RECRUITING Phase 2

Further MT for Antibiotic-Resistant Bacterial Colonization in Inpatients

NCT05835206

RECRUITING Phase 4

Anti-Inflammatory Challenge in Schizophrenia

NCT05823532

RECRUITING NA

A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis

NCT06350149

RECRUITING Phase 3

Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter

NCT06257576

RECRUITING Phase 3

Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3

NCT05834478

RECRUITING NA

AB Gait Estim Neurophysiology

NCT06430164

RECRUITING NA

Trial of Community-based Patient Navigation

NCT05588245

RECRUITING NA

Non-Invasive Diagnostic Tests for MASLD in Pediatric Population

NCT06218589

RECRUITING Phase 2

Arginine Replacement Therapy in COVID-19

NCT05855330

RECRUITING NA

Health Behavior Intervention for Adults With Type 1 Diabetes

NCT05823142

RECRUITING Phase 2

Inflammation and Depression in People With HIV

NCT05849038

RECRUITING Phase 4

Dopaminergic Therapy for Anhedonia - 2

NCT06075771

RECRUITING Phase 2

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

NCT05998135

RECRUITING Phase 1

Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma

NCT05400603

RECRUITING Phase 4

Bone Marrow and Peripheral Blood Immune Responses Study

NCT05616546

RECRUITING Phase 2

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

NCT05756569

RECRUITING NA

Rural Expanded Access to OUD Care & Linkage Using Toxicologists for Telehealth Initiated Treatment

NCT05711056

RECRUITING NA

Effect of Personalized Pain Coaches After Orthopaedic Surgery for Patients With Sports Medicine Injuries

NCT05821699

RECRUITING NA

Virtual Rehabilitation in HCT

NCT05943964

RECRUITING NA

Perilunate Management

NCT05824078

RECRUITING NA

FEED-Cystic Fibrosis (FEED-CF)

NCT05766774

RECRUITING

Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

NCT05877859

RECRUITING NA

Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study

NCT05065840

RECRUITING Phase 2

Ondansetron As a Strategy for Reducing Propofol Injection Pain in Pediatrics: a Randomized Controlled Trial

NCT05378113

RECRUITING NA

Caregiving While Black

NCT05772689

RECRUITING NA

A Web-Based Dyadic Intervention for Colorectal Cancer

NCT05663203

RECRUITING Phase 4

Low Dose Naltrexone for Pain in Patients With HIV

NCT05537935

RECRUITING NA

Spatial-Motor Stroke-Rehab Study

NCT06053320

RECRUITING Phase 4

Durability of Vaccine Responses

NCT05801978

RECRUITING

DELTA (Detecting and Predicting Atrial Fibrillation in Post-Stroke Patients)

NCT05795842

RECRUITING NA

A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy

NCT05488145

RECRUITING NA

Symptom Care at Home-Heart Failure

NCT04347759

RECRUITING

Screening for Autism in 9-Month-Olds by Measuring Social Visual Engagement

NCT05916430

RECRUITING Phase 4

Ketorolac in Upper Extremity Tendinopathy and Arthropathy

NCT05292339

RECRUITING NA

Mechanisms of Behavioral Activation (BA)

NCT05548244

RECRUITING Phase 4

Perioperative Steroid Dosing on the APR in AIS

NCT05561725

RECRUITING NA

Disrupting Fear-based Memory Consolidation

NCT05560113

RECRUITING Phase 2

Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD

NCT05928936

RECRUITING Early Phase 1

Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine

NCT05327699

← Previous Page 3 of 25 Next →

Phase Distribution

PhaseTrial count
Phase 1 154
Phase 2 190
Phase 3 36
Phase 4 134

What is open in the Emory University pipeline

208 recruiting of 1,208 indexed (17% open); 767 completed (63%).

Phase mix: 170 late (III/IV) vs 344 early (I/II) (early-phase heavy).

Top condition: Depression (12 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Emory University: open-pipeline peers nationwide

Peers matched on 1,208 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 12%14%16%18%20% Total trials Recruiting share Emory UniversityNorthwestern UniversityUniversity of PittsburghNYU Langone HealthUniversity of Alabama at BirminghamBaylor Research InstituteNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Hunter College of City University of New YorkOchsner Health System
Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,208 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

What to do with this Emory University page

1,208 registered trials is a research-attention snapshot, not an endorsement of Emory University or any single study.

  • 208 of Emory University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Depression is the condition Emory University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Emory University pipeline card: 1,208 registered trials from official public datasets.Report a data error.